EMA Authorised: Pemetrexed medac (pemetrexed) — medac Gesellschaft für klinische Spezialpräparate mbH

View source ↗

Summary

EMA authorised medac's pemetrexed medicine for use in non-small cell lung cancer and malignant mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed medac (pemetrexed)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Mesothelioma. MAH: medac Gesellschaft für klinische Spezialpräparate mbH. Decision date: 28/05/2025